{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:00:21Z","timestamp":1787014821101,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":3841,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1111\/j.1523-1755.2005.09500.x","type":"journal-article","created":{"date-parts":[[2005,5,6]],"date-time":"2005-05-06T13:58:47Z","timestamp":1115387927000},"page":"S1-S7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"S95","title":["Consequences and management of hyperphosphatemia in patients with renal insufficiency"],"prefix":"10.1016","volume":"67","author":[{"given":"Eli A.","family":"Friedman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0010","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0272-6386(03)00867-9","article-title":"Dialysis Outcomes Quality Initiative Clinical Practice Guidelines. Developing clinical performance measures based on the Dialysis Outcomes Quality Initiative Clinical Practice Guidelines: Process, outcomes, and implications","volume":"42","author":"Sugarman","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0015","first-page":"185","article-title":"Secondary hyperparathyroidism in chronic kidney disease: Clinical consequences and challenges","volume":"31","author":"Michael","year":"2004","journal-title":"Nephrol Nurs J"},{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0020","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.0894-0959.2004.17308.x","article-title":"The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease","volume":"17","author":"Goodman","year":"2004","journal-title":"Semin Dial"},{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1053\/jarr.2002.34846","article-title":"Pathogenesis of parathyroid dysfunction in end-stage renal disease","volume":"9","author":"Silver","year":"2002","journal-title":"Adv Ren Replace Ther"},{"issue":"Suppl","key":"10.1111\/j.1523-1755.2005.09500.x_bb0030","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1046\/j.1523-1755.1999.07304.x","article-title":"Pathogenesis of secondary hyperparathyroidism","volume":"73","author":"Slatopolsky","year":"1999","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0035","first-page":"F157","article-title":"Vitamin D","volume":"277","author":"Brown","year":"1999","journal-title":"Am J Physiol"},{"issue":"Suppl 3","key":"10.1111\/j.1523-1755.2005.09500.x_bb0040","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ndt\/11.supp3.22","article-title":"A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism","volume":"11","author":"Martinez","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0045","doi-asserted-by":"crossref","first-page":"F367","DOI":"10.1152\/ajprenal.00061.2002","article-title":"Mechanisms of secondary hyperparathyroidism","volume":"283","author":"Silver","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0050","doi-asserted-by":"crossref","first-page":"F663","DOI":"10.1152\/ajprenal.00332.2002","article-title":"Characterization of cis-acting element in renal NaPi-2 cotransporter mRNA that determines mRNA stability","volume":"284","author":"Moz","year":"2003","journal-title":"Am J Physiol Renal Physiol"},{"issue":"Suppl 1","key":"10.1111\/j.1523-1755.2005.09500.x_bb0055","doi-asserted-by":"crossref","first-page":"i9","DOI":"10.1093\/ndt\/gfh1002","article-title":"The importance of bone health in end-stage renal disease: Out of the frying pan, into the fire?","volume":"19","author":"Malluche","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0060","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/108155890405200127","article-title":"Biologic effects of parathyroid hormone metabolites: Implications for renal bone disease","volume":"52","author":"Akhtar","year":"2004","journal-title":"J Investig Med"},{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0065","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.mnh.0000133984.47806.00","article-title":"Harnessing the parathyroids to create stronger bones","volume":"13","author":"Silver","year":"2004","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0070","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal disease","volume":"32","author":"Foley","year":"1998","journal-title":"Am J Kidney Dis"},{"issue":"12 Suppl","key":"10.1111\/j.1523-1755.2005.09500.x_bb0075","first-page":"S16","article-title":"Epidemiology of cardiovascular disease in chronic renal disease","volume":"9","author":"Foley","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0080","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/01.RLU.0000048685.66762.C2","article-title":"The use of bone scintigraphy to evaluate metastatic calcification caused by end-stage renal disease and secondary hyperparathyroidism","volume":"28","author":"Kok","year":"2003","journal-title":"Clin Nucl Med"},{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0085","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0272-6386(96)90363-7","article-title":"Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients","volume":"27","author":"Braun","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0090","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0095","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/j.jrn.2003.09.008","article-title":"The effect of diet education on the laboratory values and knowledge of hemodialysis patients with hyperphosphatemia","volume":"14","author":"Ford","year":"2004","journal-title":"J Ren Nutr"},{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0105","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2165\/00002018-200326140-00003","article-title":"Aluminum in over-the-counter drugs: Risks outweigh benefits?","volume":"26","author":"Reinke","year":"2003","journal-title":"Drug Saf"},{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0110","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00041552-200307000-00005","article-title":"Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients","volume":"12","author":"Nolan","year":"2003","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0115","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","article-title":"Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis","volume":"342","author":"Goodman","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0120","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0272-6386(97)90009-3","article-title":"Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure","volume":"29","author":"Chertow","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0125","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0130","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/j.1523-1755.2004.00590.x","article-title":"Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study)","volume":"65","author":"Qunibi","year":"2004","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0135","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/ndt\/17.2.229","article-title":"Does calcium kill ESRD patients\u2014The skeptic's perspective","volume":"17","author":"Coladonato","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0140","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/S0140-6736(68)91816-3","article-title":"Arterial calcification after vitamin-D therapy in hyperphosphatemic renal failure","volume":"2","author":"Mallick","year":"1968","journal-title":"Lancet"},{"issue":"Suppl","key":"10.1111\/j.1523-1755.2005.09500.x_bb0145","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1046\/j.1523-1755.64.s87.20.x","article-title":"The impact of calcimimetics on mineral metabolism and secondary hyperparathyroidism in end-stage renal disease","volume":"87","author":"Block","year":"2003","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.09500.x_bb0150","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815508004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815508004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:45:12Z","timestamp":1758761112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815508004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":29,"alternative-id":["S0085253815508004"],"URL":"https:\/\/doi.org\/10.1111\/j.1523-1755.2005.09500.x","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consequences and management of hyperphosphatemia in patients with renal insufficiency","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1523-1755.2005.09500.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}